IN8BIO, Inc.
INAB1.990USD
+0.240+13.71%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
9.13MMarket Cap
LossP/E TTM
More Details of IN8BIO, Inc. Company
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
IN8BIO, Inc. Info
Ticker SymbolINAB
Company nameIN8bio Inc
IPO dateNov 12, 2020
CEOHo (William T)
Number of employees18
Security typeOrdinary Share
Fiscal year-endNov 12
AddressEmpire State Building
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10118
Phone16466006438
Websitehttps://www.in8bio.com
Ticker SymbolINAB
IPO dateNov 12, 2020
CEOHo (William T)
Company Executives of IN8BIO, Inc.
Name
Name/Position
Position
Shareholding
Change
Mr. Peter C. Brandt
Mr. Peter C. Brandt
Independent Director
Independent Director
26.23K
+26.32%
Dr. Corinne Epperly
Dr. Corinne Epperly
Independent Director
Independent Director
2.73K
--
Ms. Luba Greenwood
Ms. Luba Greenwood
Independent Director
Independent Director
261.00
--
Mr. Alan S. Roemer
Mr. Alan S. Roemer
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Emily Wang Fairbairn
Ms. Emily Wang Fairbairn
Independent Director
Independent Director
--
--
Dr. Kate Rochlin, Ph.D.
Dr. Kate Rochlin, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William T. Ho
Mr. William T. Ho
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Patrick Mccall, CPA
Mr. Patrick Mccall, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Lawrence S. Lamb, Ph.D.
Dr. Lawrence S. Lamb, Ph.D.
Co-Founder, Executive Vice President, Chief Scientific Officer
Co-Founder, Executive Vice President, Chief Scientific Officer
--
--
Dr. Jeremy R. Graff, Ph.D.
Dr. Jeremy R. Graff, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Peter C. Brandt
Mr. Peter C. Brandt
Independent Director
Independent Director
26.23K
+26.32%
Dr. Corinne Epperly
Dr. Corinne Epperly
Independent Director
Independent Director
2.73K
--
Ms. Luba Greenwood
Ms. Luba Greenwood
Independent Director
Independent Director
261.00
--
Mr. Alan S. Roemer
Mr. Alan S. Roemer
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Emily Wang Fairbairn
Ms. Emily Wang Fairbairn
Independent Director
Independent Director
--
--
Dr. Kate Rochlin, Ph.D.
Dr. Kate Rochlin, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bios Equity Partners, LP.
6.19%
Franklin Advisers, Inc.
4.10%
Transcend Partners Opportunity Fund LLC
2.32%
Two Sigma Investments, LP
2.05%
Ho (William Tai Wei)
2.02%
Other
83.32%
Shareholders
Shareholders
Proportion
Bios Equity Partners, LP.
6.19%
Franklin Advisers, Inc.
4.10%
Transcend Partners Opportunity Fund LLC
2.32%
Two Sigma Investments, LP
2.05%
Ho (William Tai Wei)
2.02%
Other
83.32%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
7.95%
Venture Capital
6.46%
Hedge Fund
4.43%
Individual Investor
3.12%
Corporation
2.32%
Investment Advisor
1.74%
Research Firm
0.57%
Other
73.40%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
51
760.78K
16.42%
-113.60K
2025Q2
62
913.62K
26.39%
-147.96K
2025Q1
67
7.37M
36.64%
+2.95M
2024Q4
64
40.67M
56.11%
+11.42M
2024Q3
66
26.31M
53.00%
+3.73M
2024Q2
66
26.43M
54.24%
+1.59M
2024Q1
62
24.15M
55.92%
+314.96K
2023Q4
58
23.08M
53.43%
+4.41M
2023Q3
55
17.49M
62.06%
+5.54M
2023Q2
52
17.21M
67.21%
+7.01M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bios Equity Partners, LP.
286.66K
6.31%
-3.00
-0.00%
Jun 30, 2025
Franklin Advisers, Inc.
189.89K
4.18%
+21.00
+0.01%
Jun 30, 2025
Transcend Partners Opportunity Fund LLC
107.42K
2.37%
--
--
Jun 30, 2025
Ho (William Tai Wei)
93.63K
2.06%
+171.00
+0.18%
Jun 30, 2025
Alyeska Investment Group, L.P.
82.48K
1.82%
+13.16K
+18.99%
Jun 30, 2025
Stonepine Capital Management, LLC
82.43K
1.82%
+82.43K
--
Jun 30, 2025
The Vanguard Group, Inc.
60.10K
1.32%
-2.00
-0.00%
Jun 30, 2025
Brandt (Peter C)
26.23K
0.58%
+5.46K
+26.32%
Apr 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 04, 2025
Merger
30→1
Date
Type
Ratio
Jun 04, 2025
Merger
30→1
FAQs
Who are the top five shareholders of IN8BIO, Inc.?
The top five shareholders of IN8BIO, Inc. are:
Bios Equity Partners, LP. holds 286.66K shares, accounting for 6.31% of the total shares.
Franklin Advisers, Inc. holds 189.89K shares, accounting for 4.18% of the total shares.
Transcend Partners Opportunity Fund LLC holds 107.42K shares, accounting for 2.37% of the total shares.
Ho (William Tai Wei) holds 93.63K shares, accounting for 2.06% of the total shares.
Alyeska Investment Group, L.P. holds 82.48K shares, accounting for 1.82% of the total shares.
Bios Equity Partners, LP. holds 286.66K shares, accounting for 6.31% of the total shares.
Franklin Advisers, Inc. holds 189.89K shares, accounting for 4.18% of the total shares.
Transcend Partners Opportunity Fund LLC holds 107.42K shares, accounting for 2.37% of the total shares.
Ho (William Tai Wei) holds 93.63K shares, accounting for 2.06% of the total shares.
Alyeska Investment Group, L.P. holds 82.48K shares, accounting for 1.82% of the total shares.
What are the top three shareholder types of IN8BIO, Inc.?
The top three shareholder types of IN8BIO, Inc. are:
Bios Equity Partners, LP.
Franklin Advisers, Inc.
Transcend Partners Opportunity Fund LLC
Bios Equity Partners, LP.
Franklin Advisers, Inc.
Transcend Partners Opportunity Fund LLC
How many institutions hold shares of IN8BIO, Inc. (INAB)?
As of 2025Q3, 51 institutions hold shares of IN8BIO, Inc., with a combined market value of approximately 760.78K, accounting for 16.42% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -9.98%.
What is the biggest source of revenue for IN8BIO, Inc.?
In --, the -- business generated the highest revenue for IN8BIO, Inc., amounting to -- and accounting for --% of total revenue.
